GeNeuro Overview

  • Founded
  • 2006
  • Status
  • Public
  • Employees
  • 19
  • Stock Symbol
  • GNRO
Stock Symbol
  • Share Price
  • $3.44
  • (As of Thursday Closing)

GeNeuro General Information


GeNeuro SA is a clinical-stage biopharmaceutical company. The company is developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis and other diseases associated with human endogenous retroviruses (HERV). Its lead therapeutic candidate is GNbAC1 which is a humanized monoclonal antibody that neutralizes a pathogenic HERV protein of the W family called pHERV-W env (also called MSRV env) that has been identified as a potential key factor in the onset and development of autoimmune diseases. Geographically, the group holds a presence in the region of France and Switzerland.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
Primary Office
  • 3, Chemin du Pré-Fleuri
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GeNeuro Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.44 $3.40 $2.14 - $5.97 $70.4M 20.5M 2.83K -$0.60

GeNeuro Financials Summary

In Thousands,
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 83,999 58,475 37,698 73,497
Revenue 0 0 8,807 16,859
EBITDA (9,242) (9,699) (9,746) (6,501)
Net Income (9,885) (10,591) (9,827) (6,583)
Total Assets 14,798 10,529 16,074 36,434
Total Debt 532 9,318 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeNeuro Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial

GeNeuro Executive Team (8)

Name Title Board Seat Contact Info
Miguel Payró Chief Financial Officer
Francois Curtin MD Chief Operating Officer & Acting Chief Medical Officer
Jean-François Arrighi Ph.D Chief Development Officer
Herve Perron Ph.D Founder & Chief Scientific Officer
David Leppert Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

GeNeuro Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeNeuro Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial